Answer
Brolucizumab (Beovu) is contraindicated in patients with active or suspected ocular or periocular infections, or active intraocular inflammation.
Sources for this answer
- Beovu 120 mg/ml solution for injection in pre filled syringeNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.3 Contraindications · Version 11Document updated
Sources checked